Slide 1: Corporate Presentation
/ Corporate Presentation RPG LIFE SCIENCES LIMITED
Slide 2: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 3: Table of Contents
Table of Contents RPG Group Snapshot RPG LS Business Overview RPG LS Financial Performance RPG LS Products Overview RPG LS Strategy
Slide 4: RPG Group: Business Portfolio
RPG Group: Business Portfolio USD 3 bn Global & diversified Indian business group Presence in key sectors of economy Global presence in over 100 countries Employee strength of over 20,000 across geographies TYRE INFRASTRUCTURE Global business of around 50% PHARMA PLANTATIONS POWER / TELECOM IT
Slide 5: RPG Group: Governance Structure
RPG Group: Governance Structure Management Board Members (MBM) Members : Chairman, CEOs, Group HR & Group Finance Purpose : Group level strategy decisions Company Board of Directors Members : Chairman, MD & Independent Directors who are experts in various fields Purpose : Company specific st
Slide 6: RPG Group: Corporate Social Responsibility
RPG Group: Corporate Social Responsibility Flagship program of RPG focusing on Preventive, Promotive , Rehabilitative and Curative Eye Care interventions ranging from children to elderly. NETRANJALI Program seeks to address the social need gap by imparting practical English fluency, both spoken and
Slide 7: RPG Group: Corporate Social Responsibility
RPG Group: Corporate Social Responsibility An integrated community project focusing on improving all round quality of life in the areas of clean drinking water, overall health and nutrition based interventions amongst others. The National Digital Literacy Mission (‘NDLM’) has a vision to empower at
Slide 8: RPG Group: Key Financials
RPG Group: Key Financials Net Revenue (Rs Cr) EBITDA (Rs Cr) EBITDA / Interest EBITDA % 18,593 17,614 1,690 1,732 15,788 13,944 1,250 1,121 10,839 943 9.6 9.3 8.7 8.0 7.9 3.6 3.5 3.6 2.8 2.9 FY11 FY12 FY13 FY14 FY15 FY11 FY12 FY13 FY14 FY15 PAT (Rs Cr) 795 714 423 429 404 FY11 FY12 FY13 FY14 FY15 No
Slide 9: RPG Group: Key Financials
RPG Group: Key Financials Net Worth (Rs Cr) ROCE ROE 4,699 Net Debt Net D/E (x) Net Debt / EBITDA 3,284 3,933 2,836 2,830 2,648 2,705 3,302 2,974 2.8 2,646 20% 18% 2.4 2.3 17% 15% 1.9 13% 1.6 13% 13% 1.0 11% 11% 11% 0.9 0.9 0.8 0.6 FY11 FY12 FY13 FY14 FY15 FY11 FY12 FY13 FY14 FY15 Net Block (Rs Cr)
Slide 10: Table of Contents
Table of Contents RPG Group Snapshot RPG LS Business Overview RPG LS Financial Performance RPG LS Products Overview RPG LS Strategy
Slide 11: RPG LS: Overview
RPG LS: Overview A fully integrated Pharmaceutical Organization with global footprints Location: Head Office in Mumbai FY15 Sales Breakup Manufacturing Locations: Navi Mumbai & Ankleshwar API, 26% R&D: DSIR approved R&D centre at Navi Mumbai Employee Base: 1150 with a PAN India presence of G
Slide 12: RPG LS: Business Overview
RPG LS: Business Overview Fermentation Technology Biotech Organic Synthesis API Global • Dosage Forms Generics • Non Branded Branded • Regulated markets • Dosage Forms Generics • India / Emerging markets 12
Slide 13: Management Team
Management Team CT. Renganathan Managing Director Rajindrra Patkar BM Sundaram Dr. Uday Bapat Sachin Raole Rabindranath Suchitra Tiwari Chief Executive Head – International Chief Scientific Officer Chief Financial Officer Nandi Head- Regulatory Domestic Formulations Business & Sr. V.P Corporate and
Slide 14: Board of Directors
RPG LS: Board of Directors Name Designation Harsh Vardhan Goenka Chairman & Non-Executive Director CT. Renganathan Managing Director Sachin Nandgaonkar Non Executive Director & Non – Independent Director C.L. Jain Non Executive & Independent Director Dr. Lalit Kanodia Non Executive & Independent Dir
Slide 15: Manufacturing Facilities
RPG LS: Manufacturing Facilities Ankleshwar, Gujarat - Formulation Plant F 1 (WHO Approved) - Formulation Plant F2 (UKMHRA Approved) - Biotech API (WHO and Korean FDA Approved Navi Mumbai, Maharashtra - API Plant – EUGMP/TGA/WHO approved 15
Slide 16: Valued partnerships in API & Global Generics
RPG LS: Valued partnerships in API & Global Generics 16
Slide 17: Domestic Formulations - Key Brands
RPG LS: Domestic Formulations - Key Brands Main Division (Therapies for Acute Ailments) Impulse (Anti-Diabetic, Cardio-vascular, Anti- Psychotic) Nephrology (Transplant, Dialysis range for Kidney) Oncology (Anti Cancer) 17
Slide 18: Table of Contents
Table of Contents RPG Group Snapshot RPG LS Business Overview RPG LS Financial Performance RPG LS Products Overview RPG LS Strategy
Slide 19: RPG LS: Key Financials
RPG LS: Key Financials 229.4 233.1 216.2 184.2 189.2 159.9 Sales (Rs Cr) EBITDA (Rs Cr) 31.9 32.8 18.8 17.9 14.0 15.1 FY10 FY11 FY12 FY13 FY14 FY15 19
Slide 20: RPG LS: Key Financials
RPG LS: Key Financials Sales of Focus Products (Rs crs) Exports (Rs Crs) 76.6 74.4 30.0 65.0 23.8 18.7 FY13 FY14 FY15 FY13 FY14 FY15 R&D opex as a % to Sales DPCO as a % to Sales 3.8% 3.4% 3.3% 26% 24% 23% FY13 FY14 FY15 FY13 FY14 FY15 20
Slide 21: RPG LS: Leverage Profile
RPG LS: Leverage Profile ST Debt (Rs Cr) 0.8 0.8 0.7 0.7 52 LT Debt (Rs Cr) 20 34 0.3 23 0.1 32 27 Total Debt / 21 33 Equity 14 11 0 0.32 FY10 FY11 FY12 FY13 FY14 FY15 21
Slide 22: Table of Contents
Table of Contents RPG Group Snapshot RPG LS Business Overview RPG LS Financial Performance RPG LS Products Overview RPG LS Strategy
Slide 23: Global Formulations
RPG LS: Global Formulations Formulation Facility at Ankleshwar Branded generics for domestic and Emerging markets (Africa ) Major presence in therapies like Nephrology, Gastro-Intestinal, Pain management, Cardio- vascular, Anti-Diabetic and Anti-Cancer RPGLS Nephrocare ranks No. 3 among Indian
Slide 24: Domestic Formulation- Therapies
RPG LS: Domestic Formulation- Therapies Division Therapy Brands Division Therapy Brands Naprosyn Pain Management Serenace Religel CNS/Neuro-Psychiatry Panicalm Nufex Anti-infective Aldactone RPGLS Main Qugyl Impulse Cardio-Vascular Losatec Vitamin Minmin Tonic Lomofen/Lomotil Arpitor GI Tricane Cvme
Slide 25: ROW Products
RPG LS: ROW Products Product Strength Brand Name Cyclosporine 25, 50, 100 mg Soft Gelatin Arpimune Azathioprine 25, 50 mg Azoran Mycophenolate Mofetil 250, 500 mg Mofetyl Tacrolimus 0.5, 1, 5 mg Immunotac Alfa Ketoanalogue 820 mg Alfalog Metformin 100, 500, 700 mg Serformin Atorvastatin 10, 20, 40,
Slide 26: Global Generics Manufacturing Facilities
RPG LS: Global Generics Manufacturing Facilities GMP compliant unit at Ankleshwar Multipurpose plant Regulated markets MHRA, UK approved 26
Slide 27: Global Generics (including Emerging Market of Far East and LATAM)
RPG LS: Global Generics (including Emerging Market of Far East and LATAM) Azathioprine - Key Product in Global Backward Integration Our Strengths State-of-the-art Generics in Azathioprine Manufacturing facility Azathioprine Global Market size : $ 169 Mn Prowess in F&D 27
Slide 28: Global Generics Products
RPG LS: Global Generics Products Other Products Lamotrigine (Tablet & OD) – 25mg, 50 mg, 100 mg Mycophenolate Mofetil – 250 mg, 500 mg Products Under Development Nicorandil – EUCTD Sodium Valproate - EUCTD Amlodipine - EUCTD 28
Slide 29: API Products
RPG LS: API Products Synthetic API- Organic Synthesis Biotech API- Fermentation Technology Around 12 APIs produced by Organic Synthesis Creating a niche in the Oncology High Value, Low Volume Niche APIs segment through fermentation Synthetic API Therapy Products technology Immuno- Azathioprine
Slide 30: API Manufacturing Facilities
RPG LS: API Manufacturing Facilities Synthetic API - 3 GMP compliant units at Navi Mumbai Fermentation Facility at Ankleshwar MF1: WHO and KFDA certified Multipurpose Less regulated markets: India / ROW Oncology Facility MF2: Dedicated Immunosuppressant ROW Markets Regulated markets MF3:
Slide 31: Table of Contents
Table of Contents RPG Group Snapshot RPG LS Business Overview RPG LS Financial Performance RPG LS Products Overview RPG LS Strategy
Slide 32: Strategy
RPG LS: Strategy Strategy – Formulation to be the Growth Engine backward integrated with API Global Formulations – Global Generic – API – Thrust on Brand Building- Customer Expansion: Development Essentially to be a Backward Integration through Focus Brands. of Sertraline and Azathioprine Stra
Slide 33: Thank You
T H A N K Y O U